Inactive Instrument

Highlights Neuralstem, Inc. Nasdaq

Equities

US64127R3021

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Jul. 11	Palisade Bio, Inc. Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product	CI
Jun. 21	Palisade Bio Provides Update on Advancement of Its Strategic Collaboration with Strand Life Sciences	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Palisade Bio, Inc. Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product	Jul. 11	CI
Palisade Bio Provides Update on Advancement of Its Strategic Collaboration with Strand Life Sciences	Jun. 21	CI
Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108	Jun. 11	CI
Palisade Bio, Inc. Announces Presentation of Positive Preclinical Data from PALI-2108	May. 21	CI
Palisade Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Palisade Bio?s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide	May. 01	CI
Palisade Bio, Inc. Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	Apr. 23	CI
Sector Update: Health Care Stocks Edge Up Tuesday Afternoon	Apr. 16	MT
Palisade Bio Shows Bioactivation of PALI-2108 in Study; Shares Rise	Apr. 16	MT
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients? Stool	Apr. 16	CI
Reverse Split: 1 of 15	Apr. 07	FA
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Palisade Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Palisade Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Palisade Bio, Inc. Announces the Appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer	23-09-11	CI
Palisade Bio, Inc. Appoints Mitchell Jones as Chief Medical Officer	23-09-11	CI
Palisade Bio, Inc. Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease	23-09-06	CI
Palisade Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Palisade Bio, Inc. Announces Topline Results from U.S. Phase 2 Profile Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions	23-08-09	CI
Palisade Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Neuralstem, Inc. Nasdaq

Equities

US64127R3021

Highlights

Filters